{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:44Z","timestamp":1793727764872,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["."],"award-info":[{"award-number":["."]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile when combined with CHOP (G-CHOP) in patients with advanced DLBCL. We present the final analysis results of the Phase III GOYA study (NCT01287741), which compared the efficacy and safety of G-CHOP versus R-CHOP in patients with previously untreated DLBCL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients aged \u2265 18\u2009years with previously untreated advanced DLBCL were randomly assigned to receive eight 21-day\u2009cycles of R or G, plus six or eight cycles of CHOP. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival, other time-to-event endpoints, and safety; investigator-assessed PFS by cell of origin subgroup was an exploratory endpoint.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 1418 patients were randomized, with 1414 included in this final analysis (G-CHOP, <jats:italic>N<\/jats:italic> = 704; R-CHOP, <jats:italic>N<\/jats:italic> = 710). Five-year PFS rates were 63.8% and 62.6% for G-CHOP and R-CHOP, respectively (stratified hazard ratio 0.94, 95% CI 0.78\u20131.12; <jats:italic>p<\/jats:italic> = 0.48). The results of the secondary efficacy endpoints did not show a benefit of G-CHOP over R-CHOP. In the exploratory analysis, a trend towards benefit with G-CHOP over R-CHOP was apparent in the patients with germinal center B cell DLBCL. The safety profile of G-CHOP was as expected, and no new safety signals were observed. More grade 3\u20135 (75.1% vs 65.8%), serious (44.4% vs 38.4%), and fatal (6.1% vs 4.4%) adverse events (AEs) were observed in the G-CHOP arm compared with the R-CHOP arm, respectively, with the most common fatal AEs being infections. A higher incidence of late-onset neutropenia occurred in the G-CHOP arm (8.7%) versus the R-CHOP arm (4.9%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The final analysis, similar to the primary analysis, did not show a PFS benefit of G-CHOP over R-CHOP in previously untreated patients with DLBCL. The results of the secondary endpoints were consistent with the primary endpoint. Further exploratory analyses and investigation of biomarkers are ongoing.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13045-020-00900-7","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T12:02:26Z","timestamp":1591444946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-9765","authenticated-orcid":false,"given":"Laurie H.","family":"Sehn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Bolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Sellam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"issue":"4","key":"900_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-Cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med."},{"issue":"Suppl 5","key":"900_CR2","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","journal-title":"Ann Oncol"},{"key":"900_CR3","unstructured":"NCCN Clinical Practice Guidelines in oncology: B-Cell Lymphomas, version 7. 2019 [Accessed 16 January 2020]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"issue":"1","key":"900_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22\u201332.","journal-title":"Blood."},{"issue":"10","key":"900_CR5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2013","unstructured":"Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031\u201342.","journal-title":"Mol Cancer Ther."},{"issue":"22","key":"900_CR6","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E Mossner","year":"2010","unstructured":"Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393\u2013402.","journal-title":"Blood."},{"issue":"23","key":"900_CR7","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","volume":"31","author":"FA Morschhauser","year":"2013","unstructured":"Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912\u20139.","journal-title":"J Clin Oncol."},{"issue":"20","key":"900_CR8","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482\u201391.","journal-title":"Blood."},{"issue":"4","key":"900_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1080\/10428194.2018.1515940","volume":"60","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leuk Lymphoma. 2019;60(4):894\u2013903.","journal-title":"Leuk Lymphoma."},{"issue":"31","key":"900_CR10","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trn\u011bn\u00fd M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337.","journal-title":"J Clin Oncol."},{"issue":"5","key":"900_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol."},{"issue":"8","key":"900_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214\u20137.","journal-title":"Blood."},{"issue":"15_suppl","key":"900_CR13","doi-asserted-by":"publisher","first-page":"8536","DOI":"10.1200\/jco.2015.33.15_suppl.8536","volume":"33","author":"B Wallden","year":"2015","unstructured":"Wallden B, Ferree S, Ravi H, Dowidar N, Hood T, Danaher P, et al. Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System. J Clin Oncol. 2015;33(15_suppl):8536.","journal-title":"J Clin Oncol"},{"issue":"14","key":"900_CR14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med."},{"issue":"12","key":"900_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med."},{"issue":"2","key":"900_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood-2015-07-658401","volume":"127","author":"JR Pon","year":"2016","unstructured":"Pon JR, Marra MA. Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma. Blood. 2016;127(2):181\u20136.","journal-title":"Blood."},{"issue":"20","key":"900_CR17","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","volume":"129","author":"D Ennishi","year":"2017","unstructured":"Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017;129(20):2760\u201370.","journal-title":"Blood."},{"issue":"26","key":"900_CR18","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2015;33(26):2848\u201356.","journal-title":"J Clin Oncol."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00900-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00900-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T23:11:50Z","timestamp":1622934710000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00900-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00900-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.Approval from the Independent Review Board (IRB)\/Independent Ethics Committee (IEC) was obtained before the start of the study, and all patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.B is employed by Genentech, Inc. and has equity ownership interests (including stock options) in F. Hoffmann-La Roche. A.K and W.L are employed by F. Hoffmann-La Roche. M.M has received honoraria from F. Hoffmann-La Roche, Celgene, Janssen, Sandoz, Novartis, Gilead, and Servier and is a member of an entity\u2019s Board of Directors or advisory committees for F. Hoffmann-La Roche, Celgene, Janssen, Sandoz, Novartis, and Gilead. D.S and G.S are employed by and have equity ownership interests (including stock options) for F. Hoffmann-La Roche. L.S has provided consultancy (including expert testimony) for F. Hoffmann-La Roche, Genentech, Inc., AbbVie, Amgen, Apobiologix, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopharm, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem; has received research funding from F. Hoffmann-La Roche and Genentech, Inc.; and has received honoraria from F. Hoffmann-La Roche, Genentech, Inc., AbbVie, Amgen, Apobiologix, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite, Karyopharm, Lundbeck, Merck, MorphoSys, Seattle Genetics, Teva, Takeda, TG Therapeutics, Verastem. M.T provides consultancy (including expert testimony) for Takeda, Bristol-Myers Squibb, Incyte, AbbVie, Amgen, F. Hoffmann-La Roche, Gilead Sciences, Janssen, Celgene, and MorphoSys and has received honoraria from Janssen, Gilead Sciences, Takeda, Bristol-Myers Squibb, Amgen, AbbVie, F. Hoffmann-La Roche, MorphoSys, and Incyte. U.V is part of the speaker\u2019s bureau for Celgene, F. Hoffmann-La Roche, Janssen, Gilead, AbbVie, and Novartis and a member of advisory committees for Janssen, Celgene, Kite, Juno Therapeutics, Gilead, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}